Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

Shares of ImmunityBio fell roughly 15% following its earnings release, even though the company reported 53% sales growth, according to a Nasdaq article that also posed the question of whether the stock is now a buy. The headline implies a disconnect between top-line expansion and investor reaction, which typically points to the market weighing factors beyond revenue, such as losses, cash burn, guidance, or the quality and sustainability of the growth. In biotech, such gaps often transmit through risk appetite and capital access, since companies with negative earnings depend on equity markets and sentiment to fund operations, making them more sensitive to shifts in the cost of capital than profitable peers. Small- and mid-cap biotech names, particularly those with concentrated product exposure, are the most vulnerable to this repricing, as sell-side reassessments can rapidly compress valuations when growth fails to translate into margin improvement. Traders should watch the company's next quarterly filing for updates on operating expenses, cash runway, and any revision to full-year guidance, as these will determine whether the sales momentum is being weighed against a deteriorating

HIGH-impact news is typically a market-moving event with multi-pip or multi-percent intraday reactions. Examples include central bank rate decisions, major CPI/NFP releases, geopolitical shocks, mega-cap earnings beats/misses, and regulatory announcements. Traders typically position-reduce or hedge ahead of scheduled HIGH-impact events, and follow the wire in real time to react to unscheduled ones (war headlines, central-bank emergency statements, surprise corporate actions). The Trading News Terminal squawk box reads every HIGH-impact headline aloud the moment it hits the wire — so active traders don't have to stare at the feed.

Active traders typically follow a three-step workflow when a market-moving headline hits the wire: (1) read the headline on the terminal or hear it on the squawk box; (2) assess whether the news is already priced in (by checking intraday price action in the seconds before) or whether it's genuinely new information; (3) act — either entering a breakout position, fading an overreaction, or tightening stops on existing trades. Trading News Terminal's Pro plan delivers wire-grade headlines within seconds of the source, with automatic audio squawk on every HIGH-impact event, so the read-assess-act cycle never waits on a refresh button.